Recent studies also implicate that XPO1 inhibitors may synergize with BRAF inhibition in human melanoma cell lines [26], supporting the concept that nuclear export inhibition may play a role as a therapeutic strategy for this disease. The gene discussed is BRAF; the disease is melanoma.